Impact of metabolizing enzymes on drug response of endocrine therapy in breast cancer. (May 2013)

• Record Type: Journal Article
• Authors: Saladores, Pilar H; Precht, Jana C; Schroth, Werner; Brauch, Hiltrud; Schwab, Matthias
• Is Part Of: Expert review of molecular diagnostics. Volume 13:Number 4(2013)
• Page Start: 349
• Page End: 365
• Publication Date: 2013-05
• Subjects: anastrozole -- aromatase inhibitors -- CYP2D6 -- endocrine therapy -- exemestane -- letrozole -- metabolism -- pharmacogenetics -- tamoxifen; Molecular diagnosis -- Periodicals; 616.0758205
• DOI: 10.1586/erm.13.26
• Languages: English
• ISSNs: 1473-7159

Abstract

Estrogen-receptor positive breast cancer accounts for 75% of diagnosed breast cancers worldwide. There are currently two major options for adjuvant treatment: tamoxifen and aromatase inhibitors. Variability in metabolizing enzymes determines their pharmacokinetic profile, possibly affecting treatment response. Therefore, prediction of therapy outcome based on genotypes would enable a more personalized medicine approach, providing optimal therapy for each patient. In this review, the authors will discuss the current evidence on the most important metabolizing enzymes in endocrine therapy, with a special focus on CYP2D6 and its role in tamoxifen metabolism.